What Genomind does

Genomind is a personalized medicine company specializing in pharmacogenetic (PGx) testing and clinical decision support for medication management, with a focus on neuropsychiatry. Founded in 2009 and headquartered in King of Prussia, Pennsylvania, the company operates a CAP-accredited, CLIA-certified, and New York State-certified clinical laboratory that analyzes a 26-gene panel (15 pharmacodynamic and 11 pharmacokinetic genes) covering guidance on 1,200+ drugs—reported to represent more than 99% of commonly prescribed medications. Sample collection is via painless cheek swab with results delivered in 3–5 business days at 99.9% laboratory accuracy.

The company's product portfolio is anchored by the Genomind PGx Test and its GenMedPro precision medicine software, a dynamic medication-management platform that combines gene-drug and drug-drug interaction analysis with social determinants of health and refreshes recommendations as patient diagnoses and medications change. Supporting products include multiple report formats (Express, NeuroPsych, Diagnosis, and the recently launched Patient Report), MentalHealthMap (a Genetic Determinants of Health wellness test), Precision Medicine Consultations with PharmD/PhD experts, and a Population Health Assessment tool for risk stratification. Distribution is multi-channel: licensed providers order through a clinician portal or directly inside Epic, athenahealth, NextGen, Practice Fusion, DrChrono, iSalus, and MEDENT (Cerner coming soon); individuals can order at-home tests via telehealth providers; and Genomind sells into long-term care organizations, ACOs, employers, and health plans.

Genomind monetizes primarily through one-time per-test fees ($599 self-pay at-home; $399 prepayment for commercially insured patients; Medicare Part B and Medicaid/Managed Medicaid coverage with $0 patient responsibility when criteria are met), supplemented by inclusion of GenMedPro software and expert consultations with each test. The company has served 400,000+ patients through 20,000+ providers and 6,000+ ordering NPIs, with reported outcomes including 40% fewer ER visits, 58% fewer hospitalizations, and approximately $1,948 in six-month per-patient cost reduction. Recent strategic moves include a January 2026 Department of Defense contract via the Defense Health Agency, an October 2025 collaboration with Adial Pharmaceuticals for Alcohol Use Disorder trials, and a November 2024 channel partnership with Evexia Diagnostics.

Name

Genomind

Legal name

Genomind, Inc.

Website

https://genomind.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

101–250 employees

Short description

Genomind is a pharmacogenetic testing company that runs a 26-gene panel from its CAP/CLIA-certified lab and delivers results through its GenMedPro decision-support software for psychiatrists, primary care providers, long-term care organizations, ACOs, and at-home telehealth patients.

Ownership category

akta.pro rank

Product category

Pharmacogenetic Testing and Precision Medicine

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Pharmacogenomics (PGx) Decision Support (HLAAANAB)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)

Keywords

• Pharmacogenetic testing
• Precision medicine software
• Genetic medication management
• Mental health diagnostics
• Clinical genomics platform

Headquarters

HQ city

Chalfont

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. PGx Testing Services: One-time payment for pharmacogenetic testing services. Self-pay option at $599 for at-home testing; $399 prepayment for commercial insurance patients. Medicare and Medicaid patients pay $0 out of pocket if coverage criteria are met. Revenue is one-time per test with no recurring component for individual patients.
2. Precision Medicine Software (GenMedPro): Software platform provided at no additional cost to providers who order Genomind PGx testing. The software analyzes gene-drug and drug-drug interactions and dynamically adjusts treatment plans. Available through the Precision Health Platform at no cost to registered providers.
3. Precision Medicine Consultations: Expert consultations with PharmD and PhD precision medicine experts included with every test at no additional cost. Services available to providers for training staff, consultations on treatment planning, and ongoing support.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Genomind provides a 26-gene pharmacogenetic (PGx) test delivered via cheek swab that analyzes how patients metabolize, respond to, and tolerate over 700 medications, with results returned in 3-5 business days at 99.9% laboratory accuracy. Test results feed into the GenMedPro precision medicine software, which dynamically evaluates gene-drug and drug-drug interactions and is bundled with expert PharmD/PhD consultations and population health risk stratification tools for healthcare providers, ACOs, long-term care facilities, employers, and health plans.

Product overview

Genomind offers a comprehensive Precision Health Platform combining pharmacogenetic (PGx) testing services with integrated software and consulting solutions. The core product portfolio includes the Genomind PGx Test (a 26-gene pharmacogenetic test covering 700+ medications) and the complementary MentalHealthMap™ wellness test. These testing products are supported by the GenMedPro™ precision medicine software, which serves as the central platform for analyzing gene-drug and drug-drug interactions. Additional offerings include Precision Medicine Consultations (access to PharmD/PhD experts), Population Health Assessment tools, and the Genomind 360 education platform. The platform supports multiple report formats (Express, NeuroPsych, Diagnosis, and Patient Reports) serving different clinical and patient needs. The architecture functions as an integrated ecosystem where test results flow into GenMedPro for ongoing medication management, supported by expert consultation services and population-level risk stratification capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• GenMedPro™: Precision medicine software platform that analyzes gene-drug and drug-drug interactions to help manage patient medication plans
• MentalHealthMap™
• Genomind 360
• Genomind PGx

Products and services

• Genomind PGx Test

Quantifiable outcome

• 40% fewer emergency room visits, 58% fewer inpatient hospitalizations, $1,948 estimated healthcare cost reduction per patient over 6 months
• +7 more outcomes

Named customers7 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability5 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered flagship and core.

• Defense Health Agency (DHA)flagshipStrategic or Co-development Partner · 29 January 2026Contract awarded to support the DHA Research & Engineering Directorate on the project 'Implementing and Assessing Pharmacogenomics for U.S. Active-Duty Service members.' Genomind will collaborate with the DHA R&E Directorate and Clinical Genomics and Precision Medicine Office to pilot pharmacogenomics implementation within the Military Health System GENESIS electronic health record. The program aims to optimize medication management and reduce adverse drug reactions for Active-Duty Service members.
• Adial PharmaceuticalscoreStrategic or Co-development Partner · 10 October 2025Collaboration to validate a cheek swab collection method for genetic testing related to Adial's AD04 program for Alcohol Use Disorder. Testing of specific SNPs achieved 100% concordance, supporting regulatory progress toward Phase 3 trials and commercial deployment. The FDA confirmed the test can be used without significant risk in Phase 3 trials.
• Evexia DiagnosticscoreChannel Partner/ Reseller/ Distributor · 6 November 2024Strategic partnership enabling Evexia Diagnostics' clinicians to access Genomind's advanced pharmacogenetic testing. Evexia, a leader in innovative diagnostic laboratory solutions serving Functional Medicine and Integrative Medicine practitioners since 2017, will distribute Genomind's testing to extend life-changing services to more providers and enhance quality of care while reducing costs for patients.
• Shore Quality PartnerscoreStrategic or Co-development Partner · 2 December 2022Partnership to help prevent adverse prescription drug events through integrated precision medication management platform. Empowers clinicians with genetic insights intended to reduce polypharmacy errors that cost thousands of lives and billions of dollars annually.
• CosáncoreStrategic or Co-development Partner · 19 July 2022Partnership to help prevent adverse prescription drug events for older adults through integrated precision medication management. Targets polypharmacy issues in aging populations.
• EpiccoreTechnology or IntegrationEMR integration partner enabling Epic users to order Genomind tests and view results directly within Epic EHR system.
• athenahealthcoreTechnology or IntegrationEMR integration partner for seamless workflow integration with athenahealth EHR platform.
• NextGen HealthcarecoreTechnology or IntegrationEMR integration partner for NextGen Healthcare EHR platform integration.
• CernercoreTechnology or IntegrationEMR integration partner (coming soon) for Cerner EHR platform integration.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory networks in the US, offering PGx and medication-management testing at scale with deep payer contracts that compete with Genomind's lab services and reimbursement strategy.
• Natera: Natera is a large, established genetic testing company with a broad portfolio (reproductive, oncology, organ health) that overlaps Genomind in clinical genomics, lab infrastructure, and channel relationships with providers and health systems.
• GeneDx: GeneDx is a clinical genomics company offering hereditary disease and rare-disease genetic testing at scale, competing for the same clinician and health-system relationships and increasingly expanding into pharmacogenomics-adjacent applications.
• Invitae: Invitae is a broad clinical genetics platform that competes in genetic testing services for clinicians and health systems and has explored pharmacogenomic content areas relevant to Genomind's product.
• Labcorp: Labcorp is a major clinical laboratory incumbent that provides pharmacogenetic and medication-management testing as part of a much broader diagnostics portfolio, directly competing for the same prescriber and ACO relationships.

Direct peers

• Myriad Genetics: Myriad Genetics is an established molecular diagnostics company with a pharmacogenetic testing offering (GeneSight) that directly competes with Genomind in psychiatric medication management and serves similar prescribers and patient populations.
• AltheaDx: AltheaDx (formerly Althea Science) is a PGx-focused diagnostics company that develops and commercializes pharmacogenetic tests for mental health and pain management, directly overlapping Genomind's neuropsychiatric positioning.
• Genomind's GeneSight competitor: Assurex Health (Myriad): GeneSight (now under Myriad) is the most direct competitor in combinatorial PGx for psychotropic prescribing, offering a similar clinician-facing report and patient value proposition.

Emerging players

• Color Health: Color Health provides genetic testing and population-health programs for employers, health plans, and clinicians, overlapping Genomind in employer/health-plan GTM, population-level risk stratification, and consumer-friendly reporting.
• 23andMe: 23andMe is a consumer-facing genetic testing company expanding into health and wellness reports, overlapping Genomind's MentalHealthMap wellness positioning, self-pay channel, and consumer marketing approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/genomind
• LinkedInlinkedin.com/company/genomind
• Instagraminstagram.com/genomind

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomind